Sugi Predict

Sugi Predict / Compounds / SCHEMBL787876

SCHEMBL787876

SCHEMBL787876

CCOC(=O)c1cccc(NS(=O)(=O)c2ccc(-c3coc(C)n3)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 1.00
▸ MEN1 O00255 2/20 0.78
▸ KMT2A Q03164 2/20 0.78
▸ NPC1 O15118 2/20 0.78
▸ PKM P14618 1/20 0.65
▸ LMNA P02545 2/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ NR2F2 P24468 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ TP53 P04637 4/20 0.55
▸ THRB P10828 2/20 0.55
▸ POLB P06746 1/20 0.53
▸ TCF4 P15884 1/20 0.53
▸ CTNNB1 P35222 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13028559 0.82 LMNA (0.73) MAPTLMNASMN1; SMN2TP53THRB
SCHEMBL17331309 0.81 TCF4 (0.79) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL788708 0.80 LMNA (0.77) MAPTMEN1KMT2ANPC1LMNA
SCHEMBL2894843 0.80 LMNA (0.71) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL16119561 0.80 LMNA (0.77) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL1726857 0.80 LMNA (0.76) MAPTKMT2APKMLMNASMN1; SMN2
SCHEMBL17331344 0.79 LMNA (0.75) MAPTLMNASMN1; SMN2TP53THRB
SCHEMBL2236072 0.79 LMNA (0.75) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL13546155 0.78 TCF4 (0.80) MAPTMEN1KMT2APKMLMNA
SCHEMBL7319886 0.77 LMNA (0.69) MAPTMEN1KMT2APKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US claimed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN claimed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO claimed
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 — — EP claimed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 — — WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 — — US disclosed
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 — — EP disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 — — US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 MAPT 845/4885MEN1 3253/4885KMT2A 1147/4885
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA MAPT 3557/4885MEN1 3971/4885KMT2A 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.